Antiplatelet therapy (AP) — Competitive Intelligence Brief

Antiplatelet therapy (AP) (Antiplatelet therapy (AP)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet agent. Area: Cardiovascular.

phase 3 Antiplatelet agent Cardiovascular Small molecule

Target snapshot

Antiplatelet therapy (AP) (Antiplatelet therapy (AP)) — Centre Hospitalier Universitaire de Saint Etienne. Antiplatelet therapy inhibits platelet aggregation to prevent thrombotic events by blocking platelet activation pathways.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Antiplatelet therapy (AP) TARGET	Antiplatelet therapy (AP)	Centre Hospitalier Universitaire de Saint Etienne	phase 3	Antiplatelet agent
Plavix	clopidogrel	Generic (originally Sanofi/BMS)	marketed	Thienopyridine antiplatelet agent	Cytochrome P450 2B6, P2Y purinoceptor 12, Sodium-dependent serotonin transporter	1997-11-17
Aspirin	acetylsalicylic acid	Bayer AG	marketed	NSAID, Antiplatelet agent	Gamma-glutamyltranspeptidase 1, Nicotinate phosphoribosyltransferase, Acid-sensing ion channel 3	1899-03-06
Aspirin + Ticagrelor	Aspirin + Ticagrelor	The First Affiliated Hospital with Nanjing Medical University	marketed	Dual antiplatelet agent	COX-1 (aspirin); P2Y12 receptor (ticagrelor)
ASA plus Clopidogrel	ASA plus Clopidogrel	Texas Cardiac Arrhythmia Research Foundation	marketed	Dual antiplatelet agent	COX-1 (aspirin); P2Y12 receptor (clopidogrel)
Switch ticagrelor to clopidogrel	Switch ticagrelor to clopidogrel	The First Affiliated Hospital with Nanjing Medical University	marketed	P2Y12 receptor antagonist; antiplatelet agent	P2Y12 receptor
Aspirin combined with clopidogrel	Aspirin combined with clopidogrel	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	marketed	Dual antiplatelet agent	Cyclooxygenase (COX) and P2Y12 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet agent class)

1. Asan Medical Center · 1 drug in this class
2. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
3. Beijing Tiantan Hospital · 1 drug in this class
4. Centre Hospitalier Universitaire de Saint Etienne · 1 drug in this class
5. China National Center for Cardiovascular Diseases · 1 drug in this class
6. Hospital Israelita Albert Einstein · 1 drug in this class
7. Icahn School of Medicine at Mount Sinai · 1 drug in this class
8. PLx Pharma · 1 drug in this class
9. Sichuan Provincial People's Hospital · 1 drug in this class
10. The George Institute for Global Health, China · 1 drug in this class